Show simple item record

dc.contributor.authorRichard, Shambavi
dc.contributor.authorChari, Ajai
dc.contributor.authorDelimpasi, Sosana
dc.contributor.authorSimonova, Maryana
dc.contributor.authorSpicka, Ivan
dc.contributor.authorPour, Ludek
dc.contributor.authorKriachok, Iryna
dc.contributor.authorDimopoulos, Meletios A
dc.contributor.authorPylypenko, Halyna
dc.contributor.authorAuner, Holger W
dc.contributor.authorLeleu, Xavier
dc.contributor.authorUsenko, Ganna
dc.contributor.authorHajek, Roman
dc.contributor.authorBenjamin, Reuben
dc.contributor.authorDolai, Tuphan Kanti
dc.contributor.authorSinha, Dinesh Kumar
dc.contributor.authorVenner, Christopher P
dc.contributor.authorGarg, Mamta
dc.contributor.authorStevens, Don Ambrose
dc.contributor.authorQuach, Hang
dc.contributor.authorJagannath, Sundar
dc.contributor.authorMoreau, Phillipe
dc.contributor.authorLevy, Moshe
dc.contributor.authorBadros, Ashraf
dc.contributor.authorAnderson, Larry D
dc.contributor.authorBahlis, Nizar J
dc.contributor.authorFacon, Thierry
dc.contributor.authorMateos, Maria Victoria
dc.contributor.authorCavo, Michele
dc.contributor.authorChang, Hua
dc.contributor.authorLandesman, Yosef
dc.contributor.authorChai, Yi
dc.contributor.authorArazy, Melina
dc.contributor.authorShah, Jatin
dc.contributor.authorShacham, Sharon
dc.contributor.authorKauffman, Michael G
dc.contributor.authorGrosicki, Sebastian
dc.contributor.authorRichardson, Paul G
dc.date.accessioned2021-07-12T13:09:39Z
dc.date.available2021-07-12T13:09:39Z
dc.date.issued2021-06-01
dc.identifier.urihttp://hdl.handle.net/10713/16162
dc.description.abstractIn the phase 3 BOSTON study, patients with multiple myeloma (MM) after 1–3 prior regimens were randomized to once-weekly selinexor (an oral inhibitor of exportin 1 [XPO1]) plus bortezomib-dexamethasone (XVd) or twice-weekly bortezomib-dexamethasone (Vd). Compared with Vd, XVd was associated with significant improvements in median progression-free survival (PFS), overall response rate (ORR), and lower rates of peripheral neuropathy, with trends in overall survival (OS) favoring XVd. In BOSTON, 141 (35.1%) patients had MM with high-risk (presence of del[17p], t[4;14], t[14;16], or ≥4 copies of amp1q21) cytogenetics (XVd, n = 70; Vd, n = 71), and 261 (64.9%) exhibited standard-risk cytogenetics (XVd, n = 125; Vd, n = 136). Among patients with high-risk MM, median PFS was 12.91 months for XVd and 8.61 months for Vd (HR, 0.73 [95% CI, (0.4673, 1.1406)], p = 0.082), and ORRs were 78.6% and 57.7%, respectively (OR 2.68; p = 0.004). In the standard-risk subgroup, median PFS was 16.62 months for XVd and 9.46 months for Vd (HR 0.61; p = 0.004), and ORRs were 75.2% and 64.7%, respectively (OR 1.65; p = 0.033). The safety profiles of XVd and Vd in both subgroups were consistent with the overall population. These data suggest that selinexor can confer benefits to patients with MM regardless of cytogenetic risk. ClinicalTrials.gov identifier: NCT03110562. © 2021 The Authors. American Journal of Hematology published by Wiley Periodicals LLC.en_US
dc.description.urihttps://doi.org/10.1002/ajh.26261en_US
dc.language.isoenen_US
dc.publisherWiley-Blackwellen_US
dc.relation.ispartofAmerican Journal of Hematologyen_US
dc.rights© 2021 The Authors. American Journal of Hematology published by Wiley Periodicals LLC.en_US
dc.subjectBOSTON clinical trialen_US
dc.subjectselinexoren_US
dc.subject.meshBortezomiben_US
dc.subject.meshDexamethasoneen_US
dc.subject.meshMultiple Myeloma--drug therapyen_US
dc.titleSelinexor, bortezomib, and dexamethasone versus bortezomib and dexamethasone in previously treated multiple myeloma: Outcomes by cytogenetic risken_US
dc.typeArticleen_US
dc.identifier.doi10.1002/ajh.26261
dc.identifier.pmid34062004
dc.source.countryUnited States


This item appears in the following Collection(s)

Show simple item record